Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (366 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 23 Feb 2022 – 20 Aug 2026, limited by HDFC NIFTY 100 Index Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HDFC NIFTY 100 Index Fund | Nifty 100 |
|---|---|---|
| 23 Feb 2022 | ₹100.00 | ₹100.00 |
| 10 Jul 2022 | ₹95.29 | ₹95.08 |
| 23 Nov 2022 | ₹106.88 | ₹106.72 |
| 09 Apr 2023 | ₹100.69 | ₹100.82 |
| 23 Aug 2023 | ₹112.38 | ₹112.09 |
| 07 Jan 2024 | ₹127.29 | ₹127.22 |
| 23 May 2024 | ₹139.14 | ₹138.84 |
| 06 Oct 2024 | ₹151.35 | ₹150.84 |
| 20 Feb 2025 | ₹136.07 | ₹135.53 |
| 06 Jul 2025 | ₹151.81 | ₹150.91 |
| 20 Nov 2025 | ₹156.09 | ₹154.89 |
| 05 Apr 2026 | ₹135.78 | ₹134.91 |
| 20 Aug 2026 | ₹148.57 | ₹147.00 |
| Metric | HDFC · Regular NAV ₹14.84 Very High risk ★★★☆☆ | Category median Index Funds · 366 funds |
|---|---|---|
| -0.90% | +5.43% | |
| +10.03% | +8.41% | |
| — | +8.95% | |
| — | +11.28% | |
| +9.22% | +7.40% | |
| +7.81% | — | |
| +12.83% | +11.37% | |
| — | +13.00% | |
| — | +11.07% | |
| Risk | ||
| 13.66% | 13.88% | |
| 0.26 | 0.25 | |
| 0.36 | 0.35 | |
| -17.49% | -16.66% | |
| Nifty 100 | — | |
| +0.29% | +0.30% | |
| 1.00 | 1.00 | |
| 100.7% | 101.3% | |
| 99.2% | 98.8% | |
| 0.81% | 0.96% | |
| ₹426.88Cr | ₹182.17Cr | |
| None | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 9% | 35% | |
| Arun Agarwal | — | |
| 23 Feb 2022 | — | |
| 100 | — | |
| 43.6% | — | |
| 0.4% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.